PD46-08 EFFICACY AND SAFETY OF MITOMYCIN GEL (UGN-101) AS AN ADJUVANT THERAPY AFTER COMPLETE ENDOSCOPIC MANAGEMENT OF UPPER TRACT UROTHELIAL CARCINOMA

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD46-08 EFFICACY AND SAFETY OF MITOMYCIN GEL (UGN-101) AS AN ADJUVANT THERAPY AFTER COMPLETE ENDOSCOPIC MANAGEMENT OF UPPER TRACT UROTHELIAL CARCINOMA Craig Labbate, Solomon Woldu, Katie Murray, Kyle Rose, Wade Sexton, Isamu Tachibana, Hristos Kaimakliotis, Joseph Jacob, Rian Dickstein, Jennifer Linehan, Alan Nieder, Marc Bjurlin, Mitchell Humphreys, Saum Ghodoussipor, Marcus Quek, Michael O'Donnell, Brian Eisner, Adam Feldman, Yair Lotan, and Surena Matin Craig LabbateCraig Labbate More articles by this author , Solomon WolduSolomon Woldu More articles by this author , Katie MurrayKatie Murray More articles by this author , Kyle RoseKyle Rose More articles by this author , Wade SextonWade Sexton More articles by this author , Isamu TachibanaIsamu Tachibana More articles by this author , Hristos KaimakliotisHristos Kaimakliotis More articles by this author , Joseph JacobJoseph Jacob More articles by this author , Rian DicksteinRian Dickstein More articles by this author , Jennifer LinehanJennifer Linehan More articles by this author , Alan NiederAlan Nieder More articles by this author , Marc BjurlinMarc Bjurlin More articles by this author , Mitchell HumphreysMitchell Humphreys More articles by this author , Saum GhodoussiporSaum Ghodoussipor More articles by this author , Marcus QuekMarcus Quek More articles by this author , Michael O'DonnellMichael O'Donnell More articles by this author , Brian EisnerBrian Eisner More articles by this author , Adam FeldmanAdam Feldman More articles by this author , Yair LotanYair Lotan More articles by this author , and Surena MatinSurena Matin More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003359.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To describe a novel application of the reverse thermal polymer gel of mitomycin C (UGN-101) as adjuvant therapy after complete endoscopic ablation of upper tract urothelial carcinoma (UTUC). METHODS: We retrospectively reviewed patients treated with UGN-101 from 15 high-volume centers. Adjuvant therapy was defined as treatment administered following visually complete endoscopic ablation. Response at primary endoscopic evaluation was defined as no visual tumor or negative biopsy. Disease free and progression free survival were estimated by the Kaplan Meier method. Ureteral stenosis and other adverse events were abstracted from the medical records. Ureteral stenosis was defined as a condition requiring ureteral stent or nephrostomy or would typically warrant stent or nephrostomy. RESULTS: Adjuvant use of UGN-101 after complete endoscopic ablation was used in 52 of 115 (45%) renal units in the oncologic analysis. At first endoscopic evaluation, 36/52 (69%) were without visible disease. At 6.8 months median follow up, the ipsilateral disease free rate was 63% (33/52). Recurrence after adjuvant UGN101 therapy was more likely in multifocal tumors compared to unifocal (HR 3.3 95% CI 1.07-9.91). Compared with UGN-101 treatment for chemoablation of measurable disease, there were significantly fewer disease detections with adjuvant therapy (p<.001). Ureteral stenosis after UGN 101 was diagnosed in 10 patients (19%) undergoing adjuvant therapy compared to 17 (29%) undergoing chemoablative therapy (p=0.28). CONCLUSIONS: In patients being considered for UGN-101, maximal endoscopic ablation prior to UGN-101 treatment may result in fewer patients with disease at first endoscopy and possibly fewer adverse events than primary chemoablative therapy. Longer follow up is needed to determine if UGN-101 after complete endoscopic ablation will lead to durable disease-free interval. Source of Funding: N/A © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1173 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Craig Labbate More articles by this author Solomon Woldu More articles by this author Katie Murray More articles by this author Kyle Rose More articles by this author Wade Sexton More articles by this author Isamu Tachibana More articles by this author Hristos Kaimakliotis More articles by this author Joseph Jacob More articles by this author Rian Dickstein More articles by this author Jennifer Linehan More articles by this author Alan Nieder More articles by this author Marc Bjurlin More articles by this author Mitchell Humphreys More articles by this author Saum Ghodoussipor More articles by this author Marcus Quek More articles by this author Michael O'Donnell More articles by this author Brian Eisner More articles by this author Adam Feldman More articles by this author Yair Lotan More articles by this author Surena Matin More articles by this author Expand All Advertisement PDF downloadLoading ...